A new article published in the International Journal of Gynaecology and Obstetrics examined the relationship between highly active antiretroviral therapy HAART and cervical cytologic abnormalities among women with HIV infection. This cross sectional prospective study was undertaken on 110 women attending an HIV clinic in Nnewi Nigeria between January 2016 and January 2017. The findings identified cervical cytologic abnormalities in 28.2 participants. The use of HAART for 2 5 years was associated with a reduction in risk of cervical cytologic abnormalities while this risk was further reduced when HAART was taken for more than 5 years. Other factors that significantly reduced risk of cervical cytologic abnormalities included a CD4 cluster of differentiation 4 count of 300 cells per mL or more age 30 years or older and time since HIV diagnosis of more than 5 years. Furthermore on multivariate analysis risk of cervical cytologic abnormalities among the women were significantly reduced by use of HAART for more than 5 years and CD4 count of 300 cells per mL or more. Therefore it was inferred that long term use of HAART and CD4 count of 300 cells per mL or more were associated with a reduced risk of cervical cytologic abnormalities.